1
|
Hinden L, Ludyansky R, Leidershnaider S, Harris Y, Nemirovski A, Gofrit ON, Tam J, Hidas G. Peripheral Cannabinoid-1 Receptor Blockade Ameliorates Cystitis Severity. Cannabis Cannabinoid Res 2023; 8:623-633. [PMID: 35647939 PMCID: PMC10442677 DOI: 10.1089/can.2022.0077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Background: The endocannabinoid system (ECS) plays a key physiological role in bladder function and it has been suggested as a potential target for relieving lower urinary tract symptoms (LUTSs). Whereas most studies indicate that activating the ECS has some beneficial effects on the bladder, some studies imply the opposite. In this study, we investigated the therapeutic potential of peripheral cannabinoid-1 receptor (CB1R) blockade in a mouse model for LUTSs. Materials and Methods: To this end, we used the cyclophosphamide (CYP; 300 mg/kg, intraperitoneal)-induced cystitis model of bladder dysfunction, in which 12-week-old, female C57BL/6 mice were treated with the peripherally restricted CB1R antagonist, JD5037 (3 mg/kg), or vehicle for three consecutive days. Bladder dysfunction was assessed using the noninvasive voiding spot assay (VSA) as well as the bladder-to-body weight (BW) ratio and gene and protein expression levels; ECS tone was assessed at the end of the study. Results: Peripheral CB1R blockade significantly ameliorated the severity of CYP-induced cystitis, manifested by reduced urination events measured in the VSA and an increased bladder-to-BW ratio. Moreover, JD5037 normalized CYP-mediated bladder ECS tone imbalance by affecting both the expression of CB1R and the endocannabinoid levels. These effects were associated with the ability of JD5037 to reduce CYP-induced inflammatory response, manifested by a reduction in levels of the proinflammatory cytokine, tumor necrosis factor alpha (TNFα), in the bladder and serum. Conclusions: Collectively, our results highlight the therapeutic relevance of peripheral CB1R blockade in ameliorating CYP-induced cystitis; they may further support the preclinical development and clinical use of peripherally restricted CB1R antagonism for treatment of LUTSs.
Collapse
Affiliation(s)
- Liad Hinden
- Obesity and Metabolism Laboratory, Department of Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel
| | - Rami Ludyansky
- Department of Urology Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
| | - Sary Leidershnaider
- In partial fulfillment of MD requirements, Hadassah Hebrew University Medical Center, Jerusalem, Israel
| | - Yoav Harris
- In partial fulfillment of MD requirements, Hadassah Hebrew University Medical Center, Jerusalem, Israel
| | - Alina Nemirovski
- Obesity and Metabolism Laboratory, Department of Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel
| | - Ofer N. Gofrit
- Department of Urology Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
| | - Joseph Tam
- Obesity and Metabolism Laboratory, Department of Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel
| | - Guy Hidas
- Department of Urology Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
| |
Collapse
|
2
|
Abalo R, Chen C, Vera G, Fichna J, Thakur GA, López-Pérez AE, Makriyannis A, Martín-Fontelles MI, Storr M. In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat. Neurogastroenterol Motil 2015; 27:1721-35. [PMID: 26387676 PMCID: PMC4918633 DOI: 10.1111/nmo.12668] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/26/2015] [Accepted: 08/05/2015] [Indexed: 02/08/2023]
Abstract
BACKGROUND Cannabinoids have been traditionally used for the treatment of gastrointestinal (GI) symptoms, but the associated central effects, through cannabinoid-1 receptors (CB1R), constitute an important drawback. Our aims were to characterize the effects of the recently developed highly potent long-acting megagonist AM841 on GI motor function and to determine its central effects in rats. METHODS Male Wistar rats were used for in vitro and in vivo studies. The effect of AM841 was tested on electrically induced twitch contractions of GI preparations (in vitro) and on GI motility measured radiographically after contrast administration (in vivo). Central effects of AM841 were evaluated using the cannabinoid tetrad. The non-selective cannabinoid agonist WIN 55,212-2 (WIN) was used for comparison. The CB1R (AM251) and CB2R (AM630) antagonists were used to characterize cannabinoid receptor-mediated effects of AM841. KEY RESULTS AM841 dose-dependently reduced in vitro contractile activity of rat GI preparations via CB1R, but not CB2R or opioid receptors. In vivo, AM841 acutely and potently reduced gastric emptying and intestinal transit in a dose-dependent and AM251-sensitive manner. The in vivo GI effects of AM841 at 0.1 mg/kg were comparable to those induced by WIN at 5 mg/kg. However, at this dose, AM841 did not induce any sign of the cannabinoid tetrad, whereas WIN induced significant central effects. CONCLUSIONS & INFERENCES The CB1R megagonist AM841 may potently depress GI motor function in the absence of central effects. This effect may be mediated peripherally and may be useful in the treatment of GI motility disorders.
Collapse
Affiliation(s)
- R Abalo
- Área de Farmacología y Nutrición y Unidad Asociada al Instituto de Química Médica (IQM) y al Centro de Investigación de Alimentos (CIAL) del Consejo Superior de Investigaciones Científicas (CSIC); Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain,Grupo de Excelencia Investigadora URJC-Banco de Santander-Grupo multidisciplinar de investigación y tratamiento del dolor (i+DOL),Corresponding author: Abalo R, Área de Farmacología y Nutrición. Dpto. Ciencias Básicas de la Salud. Fac. Ciencias de la Salud. Universidad Rey Juan Carlos, Avda. de Atenas s/n. 28922 Alcorcón, Madrid, Spain, Telf: +34 91 488 88 54, Fax: +34 91 488 89 55,
| | - C Chen
- MedizinischeKlinik 2 der Ludwig-Maximilians Universität München, Munich, Germany,Shanghai Tenth People’s Hospital, Tongji University, School of Medicine, Shanghai, China
| | - G Vera
- Área de Farmacología y Nutrición y Unidad Asociada al Instituto de Química Médica (IQM) y al Centro de Investigación de Alimentos (CIAL) del Consejo Superior de Investigaciones Científicas (CSIC); Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain,Grupo de Excelencia Investigadora URJC-Banco de Santander-Grupo multidisciplinar de investigación y tratamiento del dolor (i+DOL)
| | - J Fichna
- MedizinischeKlinik 2 der Ludwig-Maximilians Universität München, Munich, Germany,Department of Biochemistry, Medical University of Lodz, Poland
| | - GA Thakur
- Department of Pharmaceutical Sciences, Northeastern University, Boston MA
| | - AE López-Pérez
- Grupo de Excelencia Investigadora URJC-Banco de Santander-Grupo multidisciplinar de investigación y tratamiento del dolor (i+DOL),Unidad del Dolor, Servicio de Anestesiología, Hospital General Universitario Gregorio Marañón (HGUGM), Madrid, Spain
| | - A Makriyannis
- Center for Drug Discovery, Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeaster Universtiy, Boston, MA
| | - MI Martín-Fontelles
- Área de Farmacología y Nutrición y Unidad Asociada al Instituto de Química Médica (IQM) y al Centro de Investigación de Alimentos (CIAL) del Consejo Superior de Investigaciones Científicas (CSIC); Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain,Grupo de Excelencia Investigadora URJC-Banco de Santander-Grupo multidisciplinar de investigación y tratamiento del dolor (i+DOL)
| | - M Storr
- MedizinischeKlinik 2 der Ludwig-Maximilians Universität München, Munich, Germany
| |
Collapse
|
3
|
Storr MA, Bashashati M, Hirota C, Vemuri VK, Keenan CM, Duncan M, Lutz B, Mackie K, Makriyannis A, MacNaughton WK, Sharkey KA. Differential effects of CB(1) neutral antagonists and inverse agonists on gastrointestinal motility in mice. Neurogastroenterol Motil 2010; 22:787-96, e223. [PMID: 20180825 PMCID: PMC2943391 DOI: 10.1111/j.1365-2982.2010.01478.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
BACKGROUND Cannabinoid type 1 (CB(1)) receptors are involved in the regulation of gastrointestinal (GI) motility and secretion. Our aim was to characterize the roles of the CB(1) receptor on GI motility and secretion in vitro and in vivo by using different classes of CB(1) receptor antagonists. METHODS Immunohistochemistry was used to examine the localization of CB(1) receptor in the mouse ileum and colon. Organ bath experiments on mouse ileum and in vivo motility testing comprising upper GI transit, colonic expulsion, and whole gut transit were performed to characterize the effects of the inverse agonist/antagonist AM251 and the neutral antagonist AM4113. As a marker of secretory function we measured short circuit current in vitro using Ussing chambers and stool fluid content in vivo in mouse colon. We also assessed colonic epithelial permeability in vitro using FITC-labeled inulin. KEY RESULTS In vivo, the inverse agonist AM251 increased upper GI transit and whole gut transit, but it had no effect on colonic expulsion. By contrast, the neutral antagonist AM4113 increased upper GI transit, but unexpectedly reduced both colonic expulsion and whole gut transit at high, but not lower doses. CONCLUSIONS & INFERENCES Cannabinoid type 1 receptors regulate small intestinal and colonic motility, but not GI secretion under physiological conditions. Cannabinoid type 1 inverse agonists and CB(1) neutral antagonists have different effects on intestinal motility. The ability of the neutral antagonist not to affect whole gut transit may be important for the future development of CB(1) receptor antagonists as therapeutic agents.
Collapse
Affiliation(s)
- Martin A. Storr
- Snyder Institute of Infection, Immunity & Inflammation, University Calgary, Calgary, Alberta, Canada,Division of Gastroenterology, Department of Medicine, University Calgary, Calgary, Alberta, Canada
| | - Mohammad Bashashati
- Snyder Institute of Infection, Immunity & Inflammation, University Calgary, Calgary, Alberta, Canada,Hotchkiss Brain Institute, University Calgary, Calgary, Alberta, Canada,Department of Physiology & Pharmacology, University Calgary, Calgary, Alberta, Canada
| | - Christina Hirota
- Snyder Institute of Infection, Immunity & Inflammation, University Calgary, Calgary, Alberta, Canada,Department of Physiology & Pharmacology, University Calgary, Calgary, Alberta, Canada
| | - V. Kiran Vemuri
- Center for Drug Discovery, Northeastern University, Boston, MA, USA
| | - Catherine M. Keenan
- Snyder Institute of Infection, Immunity & Inflammation, University Calgary, Calgary, Alberta, Canada,Hotchkiss Brain Institute, University Calgary, Calgary, Alberta, Canada,Department of Physiology & Pharmacology, University Calgary, Calgary, Alberta, Canada
| | - Marnie Duncan
- Snyder Institute of Infection, Immunity & Inflammation, University Calgary, Calgary, Alberta, Canada,Hotchkiss Brain Institute, University Calgary, Calgary, Alberta, Canada,Department of Physiology & Pharmacology, University Calgary, Calgary, Alberta, Canada
| | - Beat Lutz
- Department of Physiological Chemistry, University Medical Center of the Johannes Gutenberg-University, 55099 Mainz, Germany
| | - Ken Mackie
- Department of Psychological and Brain Sciences, Gill Center for Biomolecular Science, Indiana University, Bloomington, IN, USA
| | | | - Wallace K. MacNaughton
- Snyder Institute of Infection, Immunity & Inflammation, University Calgary, Calgary, Alberta, Canada,Department of Physiology & Pharmacology, University Calgary, Calgary, Alberta, Canada
| | - Keith A. Sharkey
- Snyder Institute of Infection, Immunity & Inflammation, University Calgary, Calgary, Alberta, Canada,Hotchkiss Brain Institute, University Calgary, Calgary, Alberta, Canada,Department of Physiology & Pharmacology, University Calgary, Calgary, Alberta, Canada
| |
Collapse
|